AIP Publishing LLC
AIP Publishing LLC
  • pubs.aip.org
  • AIP
  • AIP China
  • University Science Books
  • Resources
    • Researchers
    • Librarians
    • Publishing Partners
    • Topical Portfolios
    • Commercial Partners
  • Publications

    Find the Right Journal

    Explore the AIP Publishing collection by title, topic, impact, citations, and more.
    Browse Journals

    Latest Content

    Read about the newest discoveries and developments in the physical sciences.
    See What's New

    Publications

    • Journals
    • Books
    • Physics Today
    • AIP Conference Proceedings
    • Scilight
    • Find the Right Journal
    • Latest Content
  • About
    • About Us
    • News and Announcements
    • Careers
    • Events
    • Leadership
    • Contact
  • pubs.aip.org
  • AIP
  • AIP China
  • University Science Books

More Predictive In Vitro Assays May Improve Nanomedicine

  • February 1, 2022
  • Biophysics Reviews
  • News
Share:

From the Journal: Biophysics Reviews

WASHINGTON, February 1, 2022 — Messenger RNA (mRNA) vaccines are a prime example of the promising field of nanomedicine. But progress in the design and application of nanoparticles as efficient delivery vehicles for biopharmaceutics containing nucleic acid or protein drug substances is, unfortunately, remarkably slow.

Obstacles (in red) in the in vivo delivery process of intravenously (IV) applied nanoparticles. CREDIT: Simone Berger, Martin Berger, Christoph Bantz, Michael Maskos, and Ernst Wagner
Obstacles (in red) in the in vivo delivery process of intravenously (IV) applied nanoparticles.
CREDIT: Simone Berger, Martin Berger, Christoph Bantz, Michael Maskos, and Ernst Wagner

One recent obstacle to drug delivery research is an observed weak correlation between in vitro (outside a living organism) and in vivo (inside a living organism) performance. This problem was not clear in early stages, when cellular delivery of a drug nanocarrier was tested primarily within standard cell culture. With advanced pharmacological in vivo studies emerging in mice or human patients, the low reliability and validity of cell culture testing for therapeutic applications is becoming apparent.

When nanoparticles are applied intravenously, they face several obstacles that differ from in vitro situations, such as when they meet blood components. Nanoparticles are usually covered by a biomolecular multilayer (a protein corona), which alters the physiochemical properties, pharmacokinetics, and toxicity profile of the nanoparticles.

In Biophysics Reviews, from AIP Publishing, researchers in Germany provide a cutting-edge characterization of the protein corona formed around nanoparticles and its impact on the physiochemical and biological properties of these nanoparticles.

“When predicting in vivo performance from in vitro data, it is recommended to combine several analytical and biological characterization methods to get more detailed insight into the in vivo characteristics and behavior of the nanoparticles,” said Simone Berger, a co-author from Ludwig Maximilian University of Munich.

The choice of the biofluid — serum, plasma, or full blood, and animal in origin — and establishment of standardized protocols are of great importance for more consistent, robust, and comprehensive preclinical studies to derive structure-activity relationships and in vitro/in vivo correlations.

“The knowledge gained about protein corona formation can be exploited to optimize carriers for nanomedical application,” Berger said.

Information like in vivo biodistribution and off-target effects cannot be obtained from in vitro experiments, the researchers point out. But new high-throughput screening methods like the barcoding system can make in vivo investigations more effective, economical, and ethical.

Some uncertainty remains about translatability from small to large animals and humans, but bioinformatics could help identify best-fitting animal models for certain diseases.

“Alternatives to animal models, such as microfluidic ‘human-organ-on-a-chip’ technology or computational predictions, may be promising strategies for replacing animal studies in the future,” Berger said.

Nanomedicine shows “great potential to revolutionize the therapeutic landscape with a broad range of applications like cancer vaccines/immunotherapy or treatment of genetic disorders,” said Berger. “With proper and more predictive in vitro assays, the preclinical pipeline will become more efficient, faster, and economic. And importantly, animal experiments can be replaced or at least reduced.”

###

For more information:
Larry Frum
media@aip.org
301-209-3090

Article Title

Performance of nanoparticles for biomedical applications: The in vitro/in vivo discrepancy

Authors

Simone Berger, Martin Berger, Christoph Bantz, Michael Maskos, and Ernst Wagner

Author Affiliations

Ludwig Maximilian University of Munich, Johannes Gutenberg-Universität Mainz, and Fraunhofer Institute for Microengineering and Microsystems IMM


Biophysics Reviews

Biophysics Reviews publishes high quality reviews and original research covering all areas of biophysics. The journal’s focus includes experimental and theoretical research in fundamental issues in biophysics alongside its applications in other branches of science, medicine, and engineering.

https://aip.scitation.org/journal/bpr

Share:
  • Simulation Models Exercise, Age Effects on Plaque Formation in Arteries
  • Single-Use Sensor Strips Detect Cerebrospinal Fluid Leaks

Keep Up With AIP Publishing

Sign up for the AIP newsletter to receive the latest news and information from AIP Publishing.
Sign Up

AIP PUBLISHING

1305 Walt Whitman Road,
Suite 110
Melville, NY 11747
(516) 576-2200

Resources

  • Researchers
  • Librarians
  • Publishing Partners
  • Commercial Partners

About

  • About Us
  • Careers 
  • Leadership

Support

  • Contact Us
  • Terms Of Use
  • Privacy Policy

© 2025 AIP Publishing LLC
  • 𝕏